EFPIA - NEWSLETTER

EFPIA Newsletter 30 June 2016

News

24 February 2016 160224 EFPIA Statement on Brexit

EFPIA believes that the UK’s continued membership of the EU is in the best interests of...

29 June 2016 160629 PACT Industry Stakeholders Statement

On the occasion of the meeting on 29 June 2016, of the MEP Interest Group on Access to Healthcare...

Video

Investing in innovation

Pharmaceutical companies are investing 6x more in R&D than the EU’s 2020 R&D intensity target of 3%.

Powering Growth in Europe

For every Euro of direct value added by the pharmaceutical industry, more than 1.5 additional Euros are generated for the whole European economy.

Driving Employment

Throughout the labour market, 5 European jobs are supported for each role created by the pharmaceutical industry.

Events Calendar

08 SEP 2016

160908 Addressing the changing landscape for EU clinical trials Brussels, Belgium

Addressing the changing landscape for EU clinical trials

Learn more →

14 SEP 2016

160914 Life Sciences Baltics 2016 Vilnius, Lithuania

The international forum for world-class biotechnology, pharmaceutical and medial devices

Learn more →

What we are reading

WHat does brexit mean for the UK's NHS and healthcare in Europe 30 June 2016 (Forbes)

It's time to recognise the benifits of medical data use 30 June 2016 (The Guardian)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶